These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26405593)

  • 1. A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies.
    Sicard H; Bonnafous C; Morel A; Bagot M; Bensussan A; Marie-Cardine A
    Oncoimmunology; 2015 Sep; 4(9):e1022306. PubMed ID: 26405593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma.
    Marie-Cardine A; Viaud N; Thonnart N; Joly R; Chanteux S; Gauthier L; Bonnafous C; Rossi B; Bléry M; Paturel C; Bensussan A; Bagot M; Sicard H
    Cancer Res; 2014 Nov; 74(21):6060-70. PubMed ID: 25361998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Targeted Treatments for Cutaneous T-cell Lymphomas.
    Bagot M
    Indian J Dermatol; 2017; 62(2):142-145. PubMed ID: 28400633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
    Bagot M; Porcu P; Marie-Cardine A; Battistella M; William BM; Vermeer M; Whittaker S; Rotolo F; Ram-Wolff C; Khodadoust MS; Bensussan A; Paturel C; Bonnafous C; Sicard H; Azim HA; Kim YH
    Lancet Oncol; 2019 Aug; 20(8):1160-1170. PubMed ID: 31253572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas.
    Schmitt C; Marie-Cardine A; Bensussan A
    Front Immunol; 2017; 8():1010. PubMed ID: 28912774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
    Ramelyte E; Dummer R; Guenova E
    Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
    [No Abstract]   [Full Text] [Related]  

  • 7. IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma.
    Van Der Weyden C; Bagot M; Neeson P; Darcy PK; Prince HM
    Expert Opin Investig Drugs; 2018 Aug; 27(8):691-697. PubMed ID: 30001170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.
    Battistella M; Janin A; Jean-Louis F; Collomb C; Leboeuf C; Sicard H; Bonnafous C; Dujardin A; Ram-Wolff C; Kadin ME; Bensussan A; Bagot M; Michel L
    Br J Dermatol; 2016 Aug; 175(2):325-33. PubMed ID: 27037558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma.
    Welborn M; Duvic M
    Am J Clin Dermatol; 2019 Feb; 20(1):115-122. PubMed ID: 30430444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Epidermotropic T cell lymphomas as models for tumor progression].
    Bagot M; Bensussan A
    Med Sci (Paris); 2006 Feb; 22(2):192-6. PubMed ID: 16457762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of cutaneous lymphoma cells with reactive T cells and dendritic cells: implications for dendritic cell-based immunotherapy.
    Thumann P; Lüftl M; Moc I; Bagot M; Bensussan A; Schuler G; Jenne L
    Br J Dermatol; 2003 Dec; 149(6):1128-42. PubMed ID: 14674889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies against cutaneous T-cell lymphomas.
    Alaibac M
    Expert Opin Biol Ther; 2017 Dec; 17(12):1503-1510. PubMed ID: 28829215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes.
    Wechsler J; Bagot M; Nikolova M; Parolini S; Martin-Garcia N; Boumsell L; Moretta A; Bensussan A
    J Pathol; 2003 Jan; 199(1):77-83. PubMed ID: 12474229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments.
    Sivanand A; Surmanowicz P; Alhusayen R; Hull P; Litvinov IV; Zhou Y; Gniadecki R
    J Cutan Med Surg; 2019; 23(5):537-544. PubMed ID: 31353944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mast Cells Are Abundant in Primary Cutaneous T-Cell Lymphomas: Results from a Computer-Aided Quantitative Immunohistological Study.
    Eder J; Rogojanu R; Jerney W; Erhart F; Dohnal A; Kitzwögerer M; Steiner G; Moser J; Trautinger F
    PLoS One; 2016; 11(11):e0163661. PubMed ID: 27893746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Cell Heterogeneity of Cutaneous T-Cell Lymphomas Revealed Using RNA-Seq Technologies.
    Rassek K; Iżykowska K
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of cell surface molecules characterizing human cutaneous T-cell lymphomas.
    Nikolova M; Bagot M; Boumsell L; Bensussan A
    Leuk Lymphoma; 2002 Apr; 43(4):741-6. PubMed ID: 12153159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in understanding and managing cutaneous T-cell lymphomas.
    Brunner PM; Jonak C; Knobler R
    F1000Res; 2020; 9():. PubMed ID: 32419924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment.
    Geller S; Hollmann TJ; Horwitz SM; Myskowski PL; Pulitzer M
    Histopathology; 2020 Jan; 76(2):222-232. PubMed ID: 31355940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of refractory early-stage cutaneous T-cell lymphoma.
    Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
    Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.